Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech, Inc. reported a 9.8% revenue increase to RMB2,746.1 million in the first half of 2024, mainly driven by robust drug sales and expanding R&D services. The company also saw a significant profit rise to RMB386.3 million, attributed to the successful commercialization of core products and growing sales. Key developments include various global approvals for their drugs, including HANQUYOU, HANSIZHUANG, and others, which have collectively benefited hundreds of thousands of patients.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.
